(Total Views: 941)
Posted On: 08/09/2022 11:07:05 AM
Post# of 72440
Great post by Call Me Crazy, from the other board:
Connecting The Dots in Posts 392079, 392113, & 392123
A chronological timeline:
Feb. 2020 - IPIX's collaboration with NIAID begins with the shipment of Brilacidin to
NIAID funded lab to "evaluate Brilacidin’s potential antiviral and anti-
inflammatory properties in the context of viral infections, including
inhibition of SARS-CoV-2, the virus responsible for COVID-19.
Mechanism of action studies of Brilacidin...are also planned.
Oct. 2020 - IPIX & GMU announce testing results that Brilacidin "potently inhibits"
Sars-Cov-2 and has potential as a prophylactic.
Nov. 2021 - IPIX reports that Brilacidin failed to meet its primary endpoint in a
phase 2 COVID-19 clinical trial BUT Brilacidin showed potential as a
prophylactic
Dec. 2021 - NIAID announces a new 'Pandemic Preparedness Plan' and states
their existing program the 'Antiviral Program for Pandemics' (APP)
"will focus on antivirals that directly act against viral targets,
specifically for RNA viruses. Antivirals of interest will have broad
use in the outpatient setting, reducing viral burden in the early
stages of infection."[/B]
June 2022 IPIX reports NIAID sponsored testing results that show Brilacidin
Inhibits Omicron, Delta, Gamma and Alpha SARS-CoV-2 Variants.
"Related, results from new NIH/NIAID in vitro testing of Brilacidin in
over 20 acutely infectious viruses, and from the Brilacidin Phase 2
COVID-19 clinical trial, are being prepared for publication."
Additionally, "Innovation Pharmaceuticals Announces New Antiviral
Research on Brilacidin in Bunyaviruses and Alphaviruses to be
Presented at the 2022 Military Health System Research Symposium."
Aug. 2022 - Innovation Pharmaceuticals Announces NIH/NIAID-Affiliated
Researchers to Evaluate Brilacidin’s Treatment Potential Against
Monkeypox.
After 2.5 years of testing, with more to come, NIAID, I believe, has already determined Brilacidin's best antiviral role is as a prophylactic and, thus, they are attempting to establish the range of viruses that Brilacidin can inhibit.
I believe the 2022 Military Health System Research Symposium poster actually contains NIAID's intent for Brilacidin in that it " will be part of the Development of New Front Line Therapies to Prevent and Treat Endemic Viral Diseases."
I offer no timeline estimates because, as I've previously stated, the government is running IPX's Brilacidin Antiviral Program and, while I believe they are moving with deliberate speed, I don't know when we'll see the fruits of the past 2.5 years of testing and research, however, I think this collaboration will ultimately yield tens, if not hundreds, of millions of dollars for IPIX. More than enough to finance expensive clinical trials for IPIX's more lucrative indications.
Connecting The Dots in Posts 392079, 392113, & 392123
A chronological timeline:
Feb. 2020 - IPIX's collaboration with NIAID begins with the shipment of Brilacidin to
NIAID funded lab to "evaluate Brilacidin’s potential antiviral and anti-
inflammatory properties in the context of viral infections, including
inhibition of SARS-CoV-2, the virus responsible for COVID-19.
Mechanism of action studies of Brilacidin...are also planned.
Oct. 2020 - IPIX & GMU announce testing results that Brilacidin "potently inhibits"
Sars-Cov-2 and has potential as a prophylactic.
Nov. 2021 - IPIX reports that Brilacidin failed to meet its primary endpoint in a
phase 2 COVID-19 clinical trial BUT Brilacidin showed potential as a
prophylactic
Dec. 2021 - NIAID announces a new 'Pandemic Preparedness Plan' and states
their existing program the 'Antiviral Program for Pandemics' (APP)
"will focus on antivirals that directly act against viral targets,
specifically for RNA viruses. Antivirals of interest will have broad
use in the outpatient setting, reducing viral burden in the early
stages of infection."[/B]
June 2022 IPIX reports NIAID sponsored testing results that show Brilacidin
Inhibits Omicron, Delta, Gamma and Alpha SARS-CoV-2 Variants.
"Related, results from new NIH/NIAID in vitro testing of Brilacidin in
over 20 acutely infectious viruses, and from the Brilacidin Phase 2
COVID-19 clinical trial, are being prepared for publication."
Additionally, "Innovation Pharmaceuticals Announces New Antiviral
Research on Brilacidin in Bunyaviruses and Alphaviruses to be
Presented at the 2022 Military Health System Research Symposium."
Aug. 2022 - Innovation Pharmaceuticals Announces NIH/NIAID-Affiliated
Researchers to Evaluate Brilacidin’s Treatment Potential Against
Monkeypox.
After 2.5 years of testing, with more to come, NIAID, I believe, has already determined Brilacidin's best antiviral role is as a prophylactic and, thus, they are attempting to establish the range of viruses that Brilacidin can inhibit.
I believe the 2022 Military Health System Research Symposium poster actually contains NIAID's intent for Brilacidin in that it " will be part of the Development of New Front Line Therapies to Prevent and Treat Endemic Viral Diseases."
I offer no timeline estimates because, as I've previously stated, the government is running IPX's Brilacidin Antiviral Program and, while I believe they are moving with deliberate speed, I don't know when we'll see the fruits of the past 2.5 years of testing and research, however, I think this collaboration will ultimately yield tens, if not hundreds, of millions of dollars for IPIX. More than enough to finance expensive clinical trials for IPIX's more lucrative indications.
(7)
(0)Scroll down for more posts ▼
